• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MiMedx wins FDA nod for AmnioFix pivotal trial

September 7, 2017 By Sarah Faulkner

MiMedxMiMedx (NSDQ:MDXG) said today that the FDA has approved its Phase III Achilles tendonitis trial.

The 158-patient study is designed to compare the company’s AmnioFix Injectable with a saline placebo injection in the treatment of moderate to severe pain due to Achilles tendonitis.

The trial, which is the company’s second late-stage study of AmnioFix, will start enrolling patients next quarter, MiMedx reported. Its primary efficacy endpoint will be the change in visual analog scale score for patients between baseline and 90 days.

The study’s primary safety endpoint will be the proportion of product-related adverse, serious adverse and unanticipated adverse events during the first 180 days following injection between the two trial groups.

The company’s AmnioFix Injectable is a dehydrated human amnion chorion membrane injection. MiMedx said it hopes to submit a biologic license application to the FDA for tendonitis as soon as it closes out its plantar fasciitis Phase III trial.

“We are pleased to receive the FDA’s notification that we can proceed with another Phase III IND study in the orthopedic/sports medicine area. In addition to this IND study, we are planning to file for another IND by the end of this quarter. This additional IND will be for the use of our micronized dHACM in the treatment of osteoarthritis knee pain.  With the commencement of the osteoarthritis study, we will have three IND studies ongoing,” CEO Parker Petit said in prepared remarks.

“We are excited about our progress in moving our focus into the biopharmaceutical market, and we look forward to keeping our shareholders appraised on our future study results. Later this year, we will hold a meeting in New York that will include presentations by MiMedx executives and the physicians involved with our various IND studies to better inform analysts and our shareholders of these important activities.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Orthopedics, Wall Street Beat Tagged With: mimedx

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS